$11.74
Today
as of Aug 5, 16:53 ET
Last 30 days
Recent Press Releases & News
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics Says FDA Clears Phase 1/2 Trial of ATR 1072 in PRKAG2 Syndrome
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
Overview
52-week range
$12
$17
0% of range
Avg surprise (last 0)
—
Avg reaction (last 1)
-0.2%
0% positive
Latest IV / EM
3259%
EM ±902.9% · $20 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 14, 2026 | Mar/2026 | $-0.97 | — | — | — | -0.2% | earnings |
| Mon Mar 31, 2025 | Mar 2025 | $-0.44 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 13, 2026 | Jun/2026 | OTHER | — | — |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Mar 2025 |
|---|---|---|---|
| Revenue | $20M | — | $2M |
| Cost of revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | $-17M | — | $-7M |
| Net income | $-17M | — | $-7M |
| EPS (diluted) | $-0.97 | — | $-0.44 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Mar 2025 |
|---|---|---|---|
| Cash & equivalents | $268M | $0 | $0 |
| Inventory | — | — | — |
| Total current assets | $286M | $3M | — |
| Total assets | $292M | $8M | — |
| Long-term debt | — | — | — |
| Total liabilities | $58M | $71M | — |
| Total equity | $234M | $-63M | $-56M |